Nadolol in thyrotoxicosis.
1 Twenty outpatients with thyrotoxicosis received the non-selective beta-adrenoceptor antagonist nadolol as sole treatment for 3 weeks. 2 Clinical improvement as measured by reduction in thyrotoxicosis therapeutic index occurred during the first week of treatment and was continued thereafter, and was accompanied by a significant reduction in serum T3 and elevation of serum reverse T3. 3 As measured by reduction in exercise heart rate, during chronic dosing nadolol 160 mg once daily produced blockade of beta-adrenoceptors for 12 h in all patients and 24 h in all but 2. 4 Wide interindividual variability was noted in steady state plasma nadolol concentrations, in part related to age and renal function. 5 Steady state plasma nadolol concentrations were related to reduction in heart rate.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009248:Nadolol; D010366:Peak Expiratory Flow Rate; D005082:Physical Exertion; D011412:Propanolamines / Q000627:therapeutic use*; D013963:Thyroid Hormones / Q000097:blood; D013997:Time Factors
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D013963:Thyroid Hormones; D009248:Nadolol